Drug intelligence / Profile preview

sertraline + paroxetine + venlafaxine

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination of three antidepressant medications—sertraline, paroxetine, and venlafaxine. Sertraline and paroxetine are selective serotonin reuptake inhibitors (SSRIs), while venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI). All three drugs act primarily by increasing the levels of serotonin in the brain, with venlafaxine also increasing norepinephrine. These agents are individually approved for major depressive disorder and other psychiatric conditions such as anxiety disorders and post-traumatic stress disorder (PTSD)[1][2][7]. The combination of multiple antidepressants is sometimes considered in treatment-resistant depression but carries an increased risk of adverse effects, including serotonin syndrome[3][4][5]. There is limited evidence supporting the simultaneous use of all three together; most clinical experience involves combining one SSRI with an SNRI or other agent when monotherapy fails[3][4][5].

02

Targets

SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on sertraline + paroxetine + venlafaxine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sertraline + paroxetine + venlafaxine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call